Bioregulators

What constitutes a bioregulator.

A bioregulator is a regulatory molecule — most commonly a short peptide of two to seven amino acids — that participates in the body's endogenous regulatory architecture. Bioregulators act in nanomolar concentrations, translocate to the nucleus, bind specific DNA sequences, and modulate gene expression in a tissue-specific manner.

The class includes both endogenously-occurring sequences and their engineered analogs. They are biodegradable, do not bioaccumulate, and act through native regulatory pathways rather than through receptor blockade or pathway override.

The Khavinson lineage.

Across four decades of peer-reviewed research, a specific subclass of short peptides — typically two to seven amino acids — emerged as the privileged mechanism. These sequences, sometimes called the Khavinson-lineage peptides after the institutional research program that characterized them, demonstrate consistent tissue-specific gene regulation across cell culture, in-vivo mammalian models, and human clinical study.

Representative sequences from the Khavinson research program. Each peptide acts predominantly within the tissue or system from which its parent regulatory peptide originated.

Ac-X-NH2 dual-terminus modified compounds.

The native short peptides of the Khavinson lineage have a therapeutic limitation: their unprotected N- and C-termini are rapidly cleaved by aminopeptidases and carboxypeptidases in circulation, restricting them historically to injectable administration. Our laboratories developed a proprietary modification — acetylation of the N-terminus and amidation of the C-terminus — yielding Ac-X-NH2 dual-terminus modified compounds with substantially extended biological half-life.

The modification preserves the peptide's gene-regulatory activity while enabling formulation across non-injectable delivery formats — topical, transdermal, intranasal, sublingual, and oral. Seven novel Ac-X-NH2 compositions of matter were filed under provisional U.S. patent application in March 2026.

Provisional U.S. patent applications filed March 2026. Non-provisional deadline March 2027. Representative sequences shown; the full portfolio includes additional compositions and method-of-use claims across multiple indication areas.

Five non-injectable routes.

The Ac-X-NH2 modification enables therapeutic-grade bioregulator delivery across topical (creams, serums, transdermal patches), intranasal (sprays, drops), sublingual (troches, sprays, dissolvable films), oral (capsules, controlled-release oral preparations), and transdermal (extended-release patches) routes. Each format is matched to the target tissue, the therapeutic indication, and the pharmacokinetic profile required.